Table 2.
Laboratory and clinical features of healthcare workers with active hepatitis B.
| Participant | HBsAg | HBcAb | HBsAb | HBeAg | HBeAb | HBVL (IU/ml) | Serum AST (normal range: 14–36 U/L) | Liver USS | Clinical management/outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | + | + | – | – | + | ND | 33 | Normal | Active monitoring |
| 2 | + | + | – | – | + | 45 | |||
| 3 | + | + | – | + | – | 5,950,000 | 61 | Nodular mass | Died of HCC |
| 4 | + | + | – | – | + | 596 | |||
| 5 | + | + | – | – | + | 102 | 18 | Normal | Active monitoring |
| 6 | + | + | – | – | + | 5410 | 40 | Normal | Active monitoring |
| 7 | + | + | – | – | + | 544 | 39 | Normal | Active monitoring |
| 8 | + | + | – | – | + | 37 | 24 | Normal | Active monitoring |
| 9 | + | + | – | – | + | <10 | |||
| 10 | + | + | – | – | + | 994 | 25 | Normal | Active monitoring |
| 11 | + | + | – | – | + | 2050 | |||
| 12 | + | + | – | + | – | >1,000,000,000 | 64 | Increased echogenicity | Started TDF 300 mg OD |
| 13 | + | + | – | + | – | 96,800 | |||
| 14 | + | + | – | – | + | <10 | |||
| 15 | + | + | – | – | + | <10 | |||
| 16 | + | + | – | + | – | IS |
HBsAg = hepatitis B surface antigen, HBcAb = hepatitis B core antibody, HBsAb = hepatitis B surface antibody, HBeAg = hepatitis B envelope antigen, HBeAb = hepatitis B envelope antibody, HBVL = hepatitis B viral load, ALT = alanine aminotransferase, USS = ultrasound scan, ND = not detected, HCC = hepatocellular carcinoma, TDF = tenofovir disoproxil fumarate, OD = once daily, IS = insufficient sample.